Why do some people have a more severe course of COVID-19 disease than others? A genome sequence database created by an international collaboration of researchers, including many from the University of Toronto and partner hospitals, may hold the answers to this question—and many more.
...in JAMA Network Open, an observational Canadian study ties the antiviral drug combo nirmatrelvir-ritonavir (Paxlovid) to a lower risk of hospitalization or death only in very high-risk COVID-19 patients with weakened immune systems.
A pair of new studies documents initial drops—and, in some cases, rebounds—in cancer diagnoses in Canada and the United States in the first year of the COVID-19 pandemic.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/MUCU7WJPZBMQRJTTH3BLWNO2Y4.jpg)
